Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($1.15), $0.13 better than the analyst estimate of ($1.28).

The Company had $140.6 million in cash, cash equivalents, short-term investments and restricted cash as of March 31, 2016 compared to $204.0 million as of December 31, 2015, a decrease of $63.4 million. The decrease was due to the use of cash to fund the Company’s ongoing operations, commercial launch activities and related inventory build.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.